{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T16:00:05Z","timestamp":1775836805693,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1124\/molpharm.123.000692","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T21:00:20Z","timestamp":1686776420000},"page":"115-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Chemical, Pharmacological, and Structural Characterization of Novel Acrylamide-Derived Modulators of the GABAA Receptor"],"prefix":"10.1016","volume":"104","author":[{"given":"Hugo R.","family":"Arias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spencer R.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison L.","family":"Germann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia Q.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo O.","family":"Ortells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Manetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Novella","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Hamachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustav","family":"Akk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/molpharm.123.000692_bib1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1469-7793.2001.0673e.x","article-title":"Pregnenolone sulfate block of GABA(A) receptors: mechanism and involvement of a residue in the M2 region of the alpha subunit","volume":"532","author":"Akk","year":"2001","journal-title":"J Physiol"},{"key":"10.1124\/molpharm.123.000692_bib2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1124\/mol.117.110569","article-title":"GABA type A receptor activation in the allosteric coagonist model framework: relationship between EC50 and basal activity","volume":"93","author":"Akk","year":"2018","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.123.000692_bib3","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1111\/bph.15948","article-title":"Modulation of the mammalian GABAA receptor by type I and type II positive allosteric modulators of the \u03b17 nicotinic acetylcholine receptor","volume":"179","author":"Arias","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1124\/molpharm.123.000692_bib4","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1021\/acschemneuro.0c00476","article-title":"(E)-3-furan-2-yl-N-p-tolyl-acrylamide and its derivative DM489 decrease neuropathic pain in mice predominantly by \u03b17 nicotinic acetylcholine receptor potentiation","volume":"11","author":"Arias","year":"2020","journal-title":"ACS Chem Neurosci"},{"key":"10.1124\/molpharm.123.000692_bib5","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1021\/bi102001m","article-title":"Novel positive allosteric modulators of the human \u03b17 nicotinic acetylcholine receptor","volume":"50","author":"Arias","year":"2011","journal-title":"Biochemistry"},{"key":"10.1124\/molpharm.123.000692_bib6","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1080\/01616412.2021.1949684","article-title":"(E)-3-furan-2-yl-N-phenylacrylamide (PAM-4) decreases nociception and emotional manifestations of neuropathic pain in mice by \u03b17 nicotinic acetylcholine receptor potentiation","volume":"43","author":"Bagdas","year":"2021","journal-title":"Neurol Res"},{"key":"10.1124\/molpharm.123.000692_bib7","doi-asserted-by":"crossref","first-page":"10341","DOI":"10.1038\/s41598-018-28754-7","article-title":"Enhanced GABAergic actions resulting from the coapplication of the steroid 3\u03b1-hydroxy-5\u03b1-pregnane-11,20-dione (alfaxalone) with propofol or diazepam","volume":"8","author":"Cao","year":"2018","journal-title":"Sci Rep"},{"key":"10.1124\/molpharm.123.000692_bib8","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/molpharm.123.000692_bib9","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1021\/bi201772m","article-title":"Mapping general anesthetic binding site(s) in human \u03b11\u03b23 \u03b3-aminobutyric acid type A receptors with [3H]TDBzl-etomidate, a photoreactive etomidate analogue","volume":"51","author":"Chiara","year":"2012","journal-title":"Biochemistry"},{"key":"10.1124\/molpharm.123.000692_bib10","doi-asserted-by":"crossref","first-page":"19343","DOI":"10.1074\/jbc.M113.479725","article-title":"Specificity of intersubunit general anesthetic-binding sites in the transmembrane domain of the human \u03b11\u03b23\u03b32 \u03b3-aminobutyric acid type A (GABAA) receptor","volume":"288","author":"Chiara","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1124\/molpharm.123.000692_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.apha.2017.03.003","article-title":"GABAA receptors and the diversity in their structure and pharmacology","volume":"79","author":"Chua","year":"2017","journal-title":"Adv Pharmacol"},{"key":"10.1124\/molpharm.123.000692_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fncel.2014.00119","article-title":"Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives","volume":"8","author":"Deidda","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"10.1124\/molpharm.123.000692_bib13","doi-asserted-by":"crossref","first-page":"772","DOI":"10.2174\/1570159X14666160202121319","article-title":"Multiple non-equivalent interfaces mediate direct activation of GABAA receptors by propofol","volume":"14","author":"Eaton","year":"2016","journal-title":"Curr Neuropharmacol"},{"key":"10.1124\/molpharm.123.000692_bib14","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/ALN.0000000000000588","article-title":"Structural comparisons of ligand-gated ion channels in open, closed, and desensitized states identify a novel propofol-binding site on mammalian \u03b3-aminobutyric acid type A receptors","volume":"122","author":"Franks","year":"2015","journal-title":"Anesthesiology"},{"key":"10.1124\/molpharm.123.000692_bib15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2174\/1570159X19666211104142433","article-title":"Perspective on the relationship between GABAA receptor activity and the apparent potency of an inhibitor","volume":"20","author":"Germann","year":"2022","journal-title":"Curr Neuropharmacol"},{"key":"10.1124\/molpharm.123.000692_bib16","doi-asserted-by":"crossref","first-page":"e14230","DOI":"10.14814\/phy2.14230","article-title":"Steady-state activation and modulation of the synaptic-type \u03b11\u03b22\u03b32L GABAA receptor by combinations of physiological and clinical ligands","volume":"7","author":"Germann","year":"2019","journal-title":"Physiol Rep"},{"key":"10.1124\/molpharm.123.000692_bib17","doi-asserted-by":"crossref","first-page":"15451","DOI":"10.1038\/s41598-017-15571-7","article-title":"Protein-ligand blind docking using QuickVina-W with inter-process spatio-temporal integration","volume":"7","author":"Hassan","year":"2017","journal-title":"Sci Rep"},{"key":"10.1124\/molpharm.123.000692_bib18","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.conb.2011.10.007","article-title":"Functional regulation of GABAA receptors in nervous system pathologies","volume":"22","author":"Hines","year":"2012","journal-title":"Curr Opin Neurobiol"},{"key":"10.1124\/molpharm.123.000692_bib19","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/ALN.0000000000004361","article-title":"Photomotor responses in zebrafish and electrophysiology reveal varying interactions of anesthetics targeting distinct sites on \u03b3-aminobutyric acid type A receptors","volume":"137","author":"Hoyt","year":"2022","journal-title":"Anesthesiology"},{"key":"10.1124\/molpharm.123.000692_bib20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nmeth.4067","article-title":"CHARMM36m: an improved force field for folded and intrinsically disordered proteins","volume":"14","author":"Huang","year":"2017","journal-title":"Nat Methods"},{"key":"10.1124\/molpharm.123.000692_bib21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J Mol Graph"},{"key":"10.1124\/molpharm.123.000692_bib22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41586-020-2654-5","article-title":"Shared structural mechanisms of general anaesthetics and benzodiazepines","volume":"585","author":"Kim","year":"2020","journal-title":"Nature"},{"key":"10.1124\/molpharm.123.000692_bib23","doi-asserted-by":"crossref","first-page":"11599","DOI":"10.1523\/JNEUROSCI.3467-06.2006","article-title":"Identification of a GABAA receptor anesthetic binding site at subunit interfaces by photolabeling with an etomidate analog","volume":"26","author":"Li","year":"2006","journal-title":"J Neurosci"},{"key":"10.1124\/molpharm.123.000692_bib24","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1124\/mol.106.022590","article-title":"Dual potentiating and inhibitory actions of a benz[e]indene neurosteroid analog on recombinant alpha1beta2gamma2 GABAA receptors","volume":"69","author":"Li","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.123.000692_bib25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/mol.119.118927","article-title":"New author guidelines for displaying data and reporting data analysis and statistical methods in experimental biology","volume":"97","author":"Michel","year":"2020","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.123.000692_bib26","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1097\/ALN.0000000000001390","article-title":"Tryptophan and cysteine mutations in M1 helices of a1b3g2L g-aminobutyric acid type A receptors indicate distinct intersubunit sites for four intravenous anesthetics and one orphan site","volume":"125","author":"Nourmahnad","year":"2016","journal-title":"Anesthesiology"},{"key":"10.1124\/molpharm.123.000692_bib27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1124\/molpharm.121.000385","article-title":"\u03b11\u03b23\u03b32L GABAA receptor by stabilizing a novel nonconducting state","volume":"101","author":"Pierce","year":"2022","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.123.000692_bib28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1124\/pr.110.002717","article-title":"Enhancement of GABAergic activity: neuropharmacological effects of benzodiazepines and therapeutic use in anesthesiology","volume":"63","author":"Saari","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1124\/molpharm.123.000692_bib29","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1021\/acscentsci.9b00539","article-title":"Construction of a fluorescent screening system of allosteric modulators for the GABAA receptor using a turn-on probe","volume":"5","author":"Sakamoto","year":"2019","journal-title":"ACS Cent Sci"},{"key":"10.1124\/molpharm.123.000692_bib30","author":"Schr\u00f6dinger","year":"2020","journal-title":"Schr\u00f6dinger suite"},{"key":"10.1124\/molpharm.123.000692_bib31","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1124\/mol.118.113464","article-title":"Analysis of GABAA receptor activation by combinations of agonists acting at the same or distinct binding sites","volume":"95","author":"Shin","year":"2019","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.123.000692_bib32","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1124\/mol.117.109595","article-title":"The actions of drug combinations on the GABAA receptor manifest as curvilinear isoboles of additivity","volume":"92","author":"Shin","year":"2017","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.123.000692_bib33","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1124\/pr.117.014449","article-title":"International Union of Basic and Clinical Pharmacology. CVI: GABAA receptor subtype- and function-selective ligands: key issues in translation to humans","volume":"70","author":"Sieghart","year":"2018","journal-title":"Pharmacol Rev"},{"key":"10.1124\/molpharm.123.000692_bib34","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.tips.2018.03.006","article-title":"The benzodiazepine binding sites of GABAA receptors","volume":"39","author":"Sigel","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/molpharm.123.000692_bib35","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1124\/mol.118.113787","article-title":"Applying the Monod-Wyman-Changeux allosteric activation model to pseudo-steady-state responses from GABAA receptors","volume":"95","author":"Steinbach","year":"2019","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.123.000692_bib36","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1124\/mol.118.115048","article-title":"Monod-Wyman-Changeux allosteric shift analysis in mutant \u03b11\u03b23\u03b32L GABAA receptors indicates selectivity and crosstalk among intersubunit transmembrane anesthetic sites","volume":"95","author":"Szabo","year":"2019","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.123.000692_bib37","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41583-021-00443-x","article-title":"The role of GABAergic signalling in neurodevelopmental disorders","volume":"22","author":"Tang","year":"2021","journal-title":"Nat Rev Neurosci"},{"key":"10.1124\/molpharm.123.000692_bib38","doi-asserted-by":"crossref","first-page":"9478","DOI":"10.1021\/acs.chemrev.9b00055","article-title":"End-point binding free energy calculation with MM\/PBSA and MM\/GBSA: strategies and applications in drug design","volume":"119","author":"Wang","year":"2019","journal-title":"Chem Rev"},{"key":"10.1124\/molpharm.123.000692_bib39","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1523\/JNEUROSCI.22-09-03366.2002","article-title":"3beta -hydroxypregnane steroids are pregnenolone sulfate-like GABA(A) receptor antagonists","volume":"22","author":"Wang","year":"2002","journal-title":"J Neurosci"},{"issue":"Suppl_1","key":"10.1124\/molpharm.123.000692_bib40","doi-asserted-by":"crossref","first-page":"i167","DOI":"10.1093\/bja\/aex369","article-title":"Role of GABAA receptor subtypes in the behavioural effects of intravenous general anaesthetics","volume":"119","author":"Weir","year":"2017","journal-title":"Br J Anaesth"},{"key":"10.1124\/molpharm.123.000692_bib41","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1021\/acs.jmedchem.7b00681","article-title":"Free energy methods in drug design: prospects of \u201calchemical perturbation\u201d in medicinal chemistry","volume":"61","author":"Williams-Noonan","year":"2018","journal-title":"J Med Chem"},{"key":"10.1124\/molpharm.123.000692_bib42","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1002\/jcc.23702","article-title":"CHARMM-GUI Membrane Builder toward realistic biological membrane simulations","volume":"35","author":"Wu","year":"2014","journal-title":"J Comput Chem"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24000440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24000440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/molpharm.123.000692","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T08:07:43Z","timestamp":1745482063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24000440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0026895X24000440"],"URL":"https:\/\/doi.org\/10.1124\/molpharm.123.000692","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemical, Pharmacological, and Structural Characterization of Novel Acrylamide-Derived Modulators of the GABAA Receptor","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/molpharm.123.000692","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}